title: Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials.
abstract: BACKGROUND
  The purpose of this study was to determine the predictive value of breast cancer molecular subclassification regarding the benefit of adjuvant anthracycline-based chemotherapy.
  
  
  METHODS
  Tumor samples from 823 patients included in two randomized trials that compared an anthracycline-based chemotherapy with no treatment were used to construct a tissue array. Estrogen receptor (ER), Her2, epidermal growth factor receptor, cytokeratine 5/6 expressions were determined by immunohistochemistry (IHC). The potential predictive factors of treatment effect on disease-free survival (DFS) were assessed by interaction tests and multivariate analysis.
  
  
  RESULTS
  Sixty-four (8%), 98 (12%), 109 (14%) and 527 (66%) patients presented a Her2+/ER-, basal-like, Her2-/ER-/nonbasal and luminal-like breast cancer. ER expression, when assessed by IHC, was an independent predictive factor for the benefit of chemotherapy on DFS (test for interaction, P = 0.0015). The molecular subclassification significantly predicted the efficacy of chemotherapy (test for interaction, P = 0.01), but had no significant added value (P = 0.32) as compared to the ER by treatment interaction. Adjuvant chemotherapy was associated with an adjusted hazard ratio for relapse or death of 0.42 [95% confidence interval (CI): 0.17-1.05], 0.54 (95% CI: 0.27-1.08), 0.35 (95% CI: 0.18-0.68), 1.07 (95% CI: 0.81-1.41) for patients with Her2+/ER-, basal-like, Her2-/ER-/nonbasal and luminal-like tumors, respectively.
  
  
  CONCLUSIONS
  The breast cancer molecular subclassification was predictive for chemotherapy efficacy in adjuvant setting, but did not provide significant additional information to ER.
authors.affiliation: Translational research unit, Unite Propre de Recherche de l'enseignement supérieur, équipe d'accueil 03535, Villejuif, France.
authors.forename: R
authors.initials: R
authors.lastname: Conforti
authors.forename: T
authors.initials: T
authors.lastname: Boulet
authors.forename: G
authors.initials: G
authors.lastname: Tomasic
authors.forename: E
authors.initials: E
authors.lastname: Taranchon
authors.forename: R
authors.initials: R
authors.lastname: Arriagada
authors.forename: M
authors.initials: M
authors.lastname: Spielmann
authors.forename: M
authors.initials: M
authors.lastname: Ducourtieux
authors.forename: J C
authors.initials: JC
authors.lastname: Soria
authors.forename: T
authors.initials: T
authors.lastname: Tursz
authors.forename: S
authors.initials: S
authors.lastname: Delaloge
authors.forename: S
authors.initials: S
authors.lastname: Michiels
authors.forename: F
authors.initials: F
authors.lastname: Andre
mesh_terms: D018943:Anthracyclines / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000145:classification* / Q000378:metabolism*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D011237:Predictive Value of Tests; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis* / Q000378:metabolism*
chemical_list: D018943:Anthracyclines; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human